Comment from American Society of Ketamine Practitioners, Psychotherapists and Physicians
AnonymousSupportTrade association
Summary: The American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3) is nominating intravenous racemic ketamine hydrochloride for FDA label indication in refractory complex regional pain syndrome (CRPS) and refractory chronic neuropathic pain. They argue that formal approval would address a significant unmet medical need, standardize off-label practices, and improve patient access to an inexpensive generic drug.
Nomination of Racemic Ketamine Hydrochloride (IV) for a Label Indication in Refractory Complex Regional Pain Syndrome (CRPS), With a Secondary Nomination in Refractory Chronic Neuropathic Pain
SUBMITTED ON BEHALF OF: American Society of Ketamine Physicians, Psychotherapists and Practitioners